|
In 2025, Minnesota recorded eight confirmed cases of mumps. Three of the eight cases were related to international travel. Five were identified in Dec. 2025 and were residents of Hennepin and Ramsey counties. Four were unvaccinated, and one was up to date on their measles, mumps, and rubella (MMR) vaccine.
Mumps is a viral disease with symptoms that include fever, headache, muscle aches, tiredness, loss of appetite, and swollen salivary glands under the ears or jaw on one or both sides of the face (parotitis). For more information on mumps, visit Mumps Basics.
Parotitis can be caused by a number of infectious and noninfectious conditions. While mumps should remain a consideration, regardless of vaccination history, other viral causes (such as influenza, parainfluenza, coxsackie, CMV, and EBV), bacterial infections, recurrent parotitis, and noninfectious etiologies (including medication reactions, allergies, tumors, and immune-related conditions) may also be responsible. Laboratory testing and other diagnostics are recommended to distinguish etiologies that cause parotitis. For additional information on appropriate mumps testing, visit Lab Testing for Mumps at the MDH Public Health Laboratory.
The Stratis Health and MDH Long COVID Program have released a new evidence-informed tool to support providers in educating patients about long COVID and related conditions entitled COVID-19 Booster Vaccination and the Prevention of Long COVID (PDF). It summarizes findings from 12 observational studies on the use of booster vaccination as a strategy to reduce the burden of long COVID. The findings help can support conversations with patients to further encourage COVID-19 vaccination.
This resource is the fourth update released this year in this series designed to support clinicians in preventing, diagnosing, and managing long COVID. Developed with input from the Guiding Council, these tools are part of Minnesota’s broader effort to equip clinicians to better serve patients navigating complex, post-COVID conditions. To view the other resources in this series, visit Provider Education, Resources, and Interim Guidance.
The American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Family Physicians (AAFP) recommend administering the respiratory syncytial virus (RSV) vaccine, Abrysvo, to pregnant people at 32 to 36 weeks' gestation from September through January. This strategy provides maternal antibodies to infants who are born when RSV activity is high.
- Administering maternal RSV vaccine starting in September (at least one month before the start of the RSV season) and continuing through January maximizes cost-effectiveness and benefits of the vaccine.
- Administering vaccine after January may not be covered by insurance.
- Infants born before April 1 to unvaccinated pregnant people should be offered nirsevimab or clesrovimab, RSV monoclonal antibody (RSV-mAB) immunization products. Clesrovimab is only recommended for infants in their first RSV season. Nirsevimab should be used for high-risk infants who are eligible for a second dose of RSV-mAB in their second RSV season.
For additional information, visit:
On Jan. 5, HHS announced a new childhood immunization schedule that reduced universal vaccine recommendations from 17 to 11 diseases, without a vote by the Advisory Committee on Immunization Practices (ACIP). Several long-standing vaccines were shifted to shared clinical decision-making or limited to high-risk groups.
In response, MDH is directing families and providers to follow immunization schedules and guidance from AAP, AAFP, and ACOG. The evidence-based information provided by these professional organizations reflects current clinical practice and provides clarity, consistency, and confidence for providers and families. For more information visit Health Advisory: MDH Aligns with Medical Association Immunization Recommendations (PDF) and MDH aligns immunization recommendations with professional medical associations; breaks with CDC recs.
MIIC will remain aligned with published immunization schedules from AAP and AAFP. Providers should continue to use the clinical decision support available in MIIC when assessing the immunization needs of a patient. Vaccines recommended by medical associations are expected to remain covered by private insurance and will remain available through the MnVFC program. For evidence-based resources and guidance, refer to Reliable Sources of Immunization Information. MDH will continue to communicate updates regarding federal changes to immunization access or availability through Got Your Shots? News, provider and MnVFC partner messaging.
AAP has published its annually revised immunization schedule. The 2026 schedule reflects the AAP’s current recommendations for the use of vaccines licensed in the U.S. Most of the updates are minor and include clarifications in the notes and tables. Details on changes to the new schedule can be found on AAP’s 2026 immunization schedule keeps routine recommendations intact after overhaul of federal schedule.
In partnership with our MnVFC-enrolled providers, we have accomplished a lot this year! Here are some program highlights from 2025.
Vaccine distribution
MDH distributed 826,465 doses of MnVFC vaccine to enrolled providers. The top three vaccine types ordered were:
- Diphtheria, tetanus, pertussis (DTaP, Tdap, and DTaP combination vaccines with IPV, HIB, or HepB components) (20% of vaccine doses distributed).
- Influenza (all products) (17%).
- Pneumococcal 20-valent (PCV20) (10%).
Enrollments and site visits
There are 725 sites enrolled in MnVFC, and nine new sites were enrolled in 2025. In 2025, 373 total sites were visited, and 37 unannounced visits were conducted.
Thank you for your continued partnership in ensuring that Minnesota’s children are up to date on their immunizations!
|
